Clinical Trials
33 trialsEGFR Antibody Combined With PD-1 Inhibitor and Chemotherapy in R/M Nasopharyngeal Carcinoma
Sun Yat-sen University
AlloNK1
Singapore General Hospital
Chidamide in Combination With Toripalimab and Anlotinib in Recurrent/Metastatic Nasopharyngeal Carcinoma.
Sun Yat-sen University
Trial of PRO1160 (GEN1160) in Relapsed or Refractory Non-Hodgkin Lymphoma (NHL) (PRO1160-001)
Genmab
EBV Specific Cytokine Secreting TCR-T Cells in the Treatment of EBV-Positive Metastatic/Refractory Nasopharyngeal Carcinoma
Xinqiao Hospital of Chongqing
A Study of YL201 in Combination With Toripalimab and With or Without Cisplatin in Nasopharyngeal Carcinoma.
MediLink Therapeutics (Suzhou) Co., Ltd.
NACASOR
University Medical Center Groningen
Trail Evaluating Carbon Ion Radiotherapy (3 GyE Per Fraction) for Locally Recurrent Nasopharyngeal Carcinoma
Shanghai Proton and Heavy Ion Center
A Lithium-containing Mouthwash Prevention and Treatment of Oral Mucositis and Dysgeusia in Patients Undergoing Radiotherapy
West China Hospital
Dose Escalation and Expansion Study of FLX475 Monotherapy and in Combination with Pembrolizumab
RAPT Therapeutics, Inc.
Pembrolizumab and Vorinostat in Treating Patients With Recurrent Squamous Cell Head and Neck Cancer or Salivary Gland Cancer That Is Metastatic and/or Cannot Be Removed by Surgery
University of Washington
Tabelecleucel in Combination With Pembrolizumab in Subjects With Epstein-Barr Virus-associated Nasopharyngeal Carcinoma (EBV+ NPC)
Atara Biotherapeutics
A Study of ILB2109 and Toripalimab in Patients With Advanced Solid Malignancies
Innolake Biopharm
Phase 1/2a Study of VK-2019 in Patients With Epstein-Barr Virus (EBV)-Positive Nasopharyngeal Carcinoma (NPC)
Cullinan Therapeutics Inc.
The Safety and Efficacy of Multiple-dose of JS004 in Subject With HNC
Shanghai Junshi Bioscience Co., Ltd.
Cadonilimab in the Treatment of Recurrent/Metastatic Nasopharyngeal Carcinoma
Guangxi Medical University
Donafenib Monotherapy for Previously Treated Metastatic Nasopharyngeal Carcinoma
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
PD-1 Blockade and Bevacizumab Replace Cisplatin in Locoregionally Advanced Nasopharyngeal Carcinoma
Sun Yat-sen University
The Study to Evaluate Toripalimab (JS001) in Patients With Advanced GC, ESCC, NPC, HNSCC
Shanghai Junshi Bioscience Co., Ltd.
SHR-1701 in Combination With Famitinib in Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma
Jiangsu HengRui Medicine Co., Ltd.
Trail Evaluating Carbon Ion Radiotherapy for Locally Recurrent Nasopharyngeal Carcinoma
Shanghai Proton and Heavy Ion Center
Trial Evaluating Carbon Ion Radiotherapy With Concurrent Chemotherapy for Locally Recurrent Nasopharyngeal Carcinoma
Shanghai Proton and Heavy Ion Center
Demethylated Drug in the Treatment of Nasopharyngeal Carcinoma
Guilin Medical University, China
Study of Anlotinib Combined With Gemcitabine/Cisplatin in Advanced Nasopharyngeal Carcinoma
ChineseAMS
Safety and Efficacy Study of Icotinib With Intensity-modulated Radiotherapy in Nasopharyngeal Carcinoma
Taizhou Hospital
PD-1 Knockout EBV-CTLs for Advanced Stage Epstein-Barr Virus (EBV) Associated Malignancies
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Study of DC-CTL Combined With CIK for Advanced Solid Tumor
Harbin Medical University
A New EBV Related Technologies of T Cells in Treating Malignant Tumors and Clinical Application
The Second Hospital of Nanjing Medical University
HepaSphere Interventional Therapy Using Digital Subtraction Angiography(DSA) for Nasopharyngeal Carcinoma
Fuda Cancer Hospital, Guangzhou
Chemoradiation Plus Weekly c225 Against Locoregionally Advanced Nasopharyngeal Carcinoma (NPC)
Jiangsu Cancer Institute & Hospital
A Study Of Nasopharyngeal Carcinoma (NPC) Treated With Celecoxib And ZD1839
National University Hospital, Singapore
NPC-DZ
Xiangya Hospital of Central South University
Study Using Intensity-modulated Radiation Therapy in Patients With Nasopharynx Cancer to Permit Sparing of Contralateral Parotid Gland Function
AHS Cancer Control Alberta